Melanoma: More answers, more questions

Oncologist

Volumn 18, Issue 6, 2013, Pages 658-660

  Urba, Walter J ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; INTERLEUKIN 2; IPILIMUMAB; TRAMETINIB; VEMURAFENIB;

COLITIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FOLLOW UP; GENE MUTATION; HUMAN; IMMUNOTHERAPY; INFLAMMATION; MELANOMA; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; DRUG SYNERGISM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MELANOMA; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 84879492810     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0212     Document Type: Note

References (15)

1. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-1492.
2. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-4557.
3. Rosenberg SA. Raising the bar: The curative potential of human cancer immunotherapy. Sc i Transl Med 2012;4:127ps128.
4. Luke JJ, Hodi FS. Ipilimumab, vemurafenib, dabrafenib, and trametinib: Synergistic comp etitors in the clinical managment of BRAF mutant malignant melanoma. The Oncologist 2013;18:717-725.
5. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with meta static mela noma. N Engl J Me d 2011;363:711-723.
6. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526.
7. Prieto PA, Yang JC, Sherry RM et al. CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18:2039-2047.
8. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009;15:7412-7420.
9. Fecher L, Agarwala S, Hodi FS et al. Ipilimumab and its toxicities: A multidisciplinary approach. The Oncologist 2013;18:733-743.
10. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-164.
11. Postow MA, Luke JJ, Bluth MJ et al. Ipilimumab for patients with advanced mucosal melanoma. The Oncologist 2013;18:726-732.
12. Carvajal RD, Spencer SA, Lydiatt W. Mucosal melanoma: A clinically and biologically unique disease entity. J Natl Compr Canc Netw 2012;10:345-356.
13. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-1703.
14. Ribas A, Hodi FS, Callahan M et al. Hepatotox-icity with combination of vemurafenib and i pilim-umab. N Engl J Med 2013;368:1365-1366.
15. Ascierto PA, Simeone E, Giannarelli D et al. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: A possible algorithm for clinical use. J T ransl Med 2012;10:107.